UBS Group’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $47.1M | Sell |
4,943,994
-319,920
| -6% | -$2.48M | 0.01% | 1706 |
|
|
2025
Q4 | $41.1M | Sell |
5,263,914
-703,823
| -12% | -$5.09M | 0.01% | 1834 |
|
|
2025
Q3 | $45.3M | Buy |
5,967,737
+353,086
| +6% | +$2.94M | 0.01% | 1736 |
|
|
2025
Q2 | $50.3M | Buy |
5,614,651
+3,211,465
| +134% | +$29.9M | 0.01% | 1518 |
|
|
2025
Q1 | $18M | Buy |
2,403,186
+2,162,834
| +900% | +$17.4M | ﹤0.01% | 2443 |
|
|
2024
Q4 | $1.81M | Sell |
240,352
-184,667
| -43% | -$1.4M | ﹤0.01% | 4815 |
|
|
2024
Q3 | $3.23M | Buy |
425,019
+33,534
| +9% | +$255K | ﹤0.01% | 3515 |
|
|
2024
Q2 | $2.42M | Sell |
391,485
-605,070
| -61% | -$3.34M | ﹤0.01% | 3573 |
|
|
2024
Q1 | $5.06M | Buy |
996,555
+311,567
| +45% | +$1.75M | ﹤0.01% | 2960 |
|
|
2023
Q4 | $4.1M | Buy |
684,988
+379,037
| +124% | +$2.2M | ﹤0.01% | 3000 |
|
|
2023
Q3 | $2.17M | Sell |
305,951
-108,883
| -26% | -$782K | ﹤0.01% | 3367 |
|
|
2023
Q2 | $2.92M | Buy |
414,834
+8,954
| +2% | +$71.9K | ﹤0.01% | 3141 |
|
|
2023
Q1 | $3.39M | Sell |
405,880
-213,548
| -34% | -$2.06M | ﹤0.01% | 2886 |
|
|
2022
Q4 | $7.11M | Buy |
619,428
+439,894
| +245% | +$5.49M | ﹤0.01% | 2176 |
|
|
2022
Q3 | $2.26M | Buy |
179,534
+27,096
| +18% | +$349K | ﹤0.01% | 3051 |
|
|
2022
Q2 | $1.61M | Buy |
152,438
+9,290
| +6% | +$95.8K | ﹤0.01% | 3327 |
|
|
2022
Q1 | $2.33M | Sell |
143,148
-389,502
| -73% | -$6.25M | ﹤0.01% | 3290 |
|
|
2021
Q4 | $7.38M | Buy |
532,650
+194,262
| +57% | +$2.57M | ﹤0.01% | 2425 |
|
|
2021
Q3 | $4.86M | Buy |
338,388
+159,369
| +89% | +$2.51M | ﹤0.01% | 2702 |
|
|
2021
Q2 | $2.83M | Sell |
179,019
-10,397
| -5% | -$141K | ﹤0.01% | 3237 |
|
|
2021
Q1 | $1.93M | Sell |
189,416
-338,457
| -64% | -$3.49M | ﹤0.01% | 3599 |
|
|
2020
Q4 | $3.93M | Sell |
527,873
-909,182
| -63% | -$4.69M | ﹤0.01% | 2709 |
|
|
2020
Q3 | $4.94M | Buy |
1,437,055
+1,278,179
| +805% | +$5.48M | ﹤0.01% | 2221 |
|
|
2020
Q2 | $757K | Sell |
158,876
-4,924,362
| -97% | -$19.7M | ﹤0.01% | 3755 |
|
|
2020
Q1 | $10.2M | Sell |
5,083,238
-405,049
| -7% | -$1.12M | 0.01% | 1401 |
|
|
2019
Q4 | $18.9M | Buy |
5,488,287
+2,450,478
| +81% | +$6.16M | 0.01% | 1421 |
|
|
2019
Q3 | $8.7M | Buy |
3,037,809
+835,015
| +38% | +$2.6M | ﹤0.01% | 1876 |
|
|
2019
Q2 | $8.35M | Buy |
2,202,794
+1,691,681
| +331% | +$10.2M | ﹤0.01% | 1909 |
|
|
2019
Q1 | $4.16M | Buy |
511,113
+385,569
| +307% | +$3.3M | ﹤0.01% | 2359 |
|
|
2018
Q4 | $1.01M | Buy |
125,544
+13,659
| +12% | +$106K | ﹤0.01% | 3674 |
|
|
2018
Q3 | $854K | Buy |
111,885
+48,646
| +77% | +$327K | ﹤0.01% | 3992 |
|
|
2018
Q2 | $362K | Sell |
63,239
-228,140
| -78% | -$1.26M | ﹤0.01% | 4555 |
|
|
2018
Q1 | $1.39M | Buy |
291,379
+191,157
| +191% | +$982K | ﹤0.01% | 3433 |
|
|
2017
Q4 | $493K | Sell |
100,222
-13,892
| -12% | -$67.3K | ﹤0.01% | 4301 |
|
|
2017
Q3 | $598K | Buy |
114,114
+50,635
| +80% | +$259K | ﹤0.01% | 4085 |
|
|
2017
Q2 | $353K | Sell |
63,479
-8,562
| -12% | -$52.2K | ﹤0.01% | 4375 |
|
|
2017
Q1 | $605K | Sell |
72,041
-27,762
| -28% | -$193K | ﹤0.01% | 3907 |
|
|
2016
Q4 | $632K | Buy |
99,803
+11,547
| +13% | +$60.1K | ﹤0.01% | 3932 |
|
|
2016
Q3 | $389K | Buy |
88,256
+4,086
| +5% | +$16.3K | ﹤0.01% | 4082 |
|
|
2016
Q2 | $239K | Buy |
84,170
+11,335
| +16% | +$35.2K | ﹤0.01% | 4435 |
|
|
2016
Q1 | $206K | Sell |
72,835
-68,568
| -48% | -$304K | ﹤0.01% | 4476 |
|
|
2015
Q4 | $1.46M | Buy |
141,403
+69,068
| +95% | +$687K | ﹤0.01% | 3100 |
|
|
2015
Q3 | $825K | Buy |
72,335
+2,651
| +4% | +$35.4K | ﹤0.01% | 3531 |
|
|
2015
Q2 | $1.04M | Sell |
69,684
-200
| -0.3% | -$2.27K | ﹤0.01% | 3532 |
|
|
2015
Q1 | $631K | Sell |
69,884
-690
| -1% | -$7.14K | ﹤0.01% | 3942 |
|
|
2014
Q4 | $858K | Buy |
+70,574
| New | +$780K | ﹤0.01% | 3695 |
|
Other funds holding BCRX
RCM
DM
VPM
VCM
TCM
PA
VPC